NCT03403634View on ClinicalTrials.gov

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

December 23, 2020

Study Completion Date

August 29, 2021

Conditions
Metastatic Carcinoma in the LiverRecurrent Colorectal CarcinomaStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7
Interventions
DRUG

Celecoxib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Recombinant Interferon Alfa-2b

Given IV

DRUG

Rintatolimod

Given IV

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER

NCT03403634 - Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | Biotech Hunter | Biotech Hunter